Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsAndrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Estimating the term…
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
A fusion protein comprising a peptide consisting of the amino acid sequence of ILLQASVQV (SEQ ID NO:1) and the 80 N-terminal amino acids of the HLA-DR antigen associated invariant chain (Ii).
An in vitro method for producing activated T lymphocytes, comprising contacting in vitro T cells with antigen loaded human HLA-A*02:01 expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide consisting of the amino acid sequence of ILLQASVQV (SEQ ID NO:
A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of ILLQASVQV (SEQ ID NO:
A method for producing a peptide consisting of the amino acid sequence of ILLQASVQV (SEQ ID NO:
Dependencies are inferred from the claim text.